Peripheral Markers of Phenotypic Heterogeneity in COPD
Peripheral Markers of Phenotypic Heterogeneity in COPD
批准号:
7231226
负责人:
FRANK SCIURBA
金额:
$84.38万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-12-01 至 2011-11-30
关键词:
AnatomyBiologicalBiological AssayBiological MarkersBlood specimenBody CompositionBody measure procedureCategoriesCell physiologyCharacteristicsChronic Obstructive Airway DiseaseClassificationClinicalComplexConditionCross-Sectional StudiesDataDevelopmentDiagnosisDiffuseDiseaseDisease ProgressionDoseEarly DiagnosisEnd PointEnvironmental Risk FactorEvaluationEventExercise stress testFutureGene TargetingGeneticGenomicsHeterogeneityHistologicImmuneImmune responseImpairmentIndividualIntervention StudiesInterviewInvasiveLaboratoriesLeadLungLung TransplantationMeasurableMeasurementMeasuresModelingMolecularMorphologyMucous body substanceOperative Surgical ProceduresOscillometryPathologicPathologyPatientsPerformancePeripheralPersonal SatisfactionPhenotypePhysiologicalPhysiologyProcessProgressive DiseasePulmonary EmphysemaPulmonary Function Test/Forced Expiratory Volume 1Pulmonary function testsQuality of lifeQuestionnairesRangeRateRecruitment ActivityRelative (related person)Research PersonnelRiskScoreSerumSeveritiesSeverity of illnessSmokerSpirometryStandards of Weights and MeasuresStructure of parenchyma of lungSubgroupSurrogate MarkersSymptomsSyndromeSystemT-Cell ActivationT-LymphocyteTechniquesTechnologyTestingTherapeuticTherapeutic InterventionThickTobacco smokeVariantWalkingairway inflammationairway remodelingbasecohortcytokinedisease natural historyfunctional disabilityindexinginnovationinsightmortalitynoveloutcome forecastperipheral bloodpredictive modelingprogramsrespiratorytherapeutic targettool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The classification of COPD based simply on magnitude of forced expiratory flow abnormality, is
inadequate and of limited value in individualizing therapeutic interventions to influence the natural history of
the disease. Our global hypothesis is that "COPD is a heterogeneous group of definable anatomic and
physiologic disease processes, each with its own molecular and cellular processes that determine
disease manifestation and progression." We propose to use 2 well established cohorts of current and
former smokers to efficiently recruit and execute a cross sectional study of 800 subjects with a wide range of
disease manifestation and then to follow 450 of them longitudinally over a 2-3 year course.
(SA1): To use quantitative CT (QCT) determinants of airway remodeling and emphysema and their
associations with other physiologic and functional indices of COPD to define unique clinicopathologic
disease subclasses or phenotypes, and (SA2) To Associate Peripheral Blood Molecular
and Cellular Biomarkers with Unique Clinical and Lung Histopathologic Phenotypes. We believe,
based upon preliminary data, that ascertainable variation in immune cell function, cytokine expression, and
genetic factors are different between and can be used to distinguish unique pathophysiologic subsets of
patients. We aim nothing short of providing justification for reclassification of COPD into more biologically
relevant categories that could direct development of more effective patient specific therapies.
In our (SA3) we further explore the recent observations from the laboratory of our co-investigator, Dr. J
Hogg, of a dramatic association between peripheral airway luminal mucous content LC% and poor survival.
Findings of surrogate markers associated with this process could have immense importance because, to
date, we have been unable to identify an association between the severity of LC% and any clinical or
physiologic feature. We hypothesize that: Molecular and cellular biomarkers and QCT variables of
COPD, in a subgroup of severe patients characterized prior to lung transplantation, are associated
with severity of luminal content (LC) occlusion of peripheral airways measured in lung tissue using
standard morphometric techniques. Identification of non-invasive surrogates for this condition, could
have major implications in determining prognosis or targeting individual therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IGF::OT::IGF LTRC CLINICAL CENTER - TASK ORDER 2 - 03/01/2017 - 02/28/2018 - CAN 17-8470204
-
批准号:9514443
-
项目类别:
-
资助金额:$22.01万
-
财政年份:2017
-
负责人:FRANK SCIURBA
-
依托单位:
IGF::OT::IGF LTRC CLINICAL CENTER - TASK ORDER 001; SUBJECT CHARACTERIZATION AND TISSUE PROCUREMENT
-
批准号:9304632
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2016
-
负责人:FRANK SCIURBA
-
依托单位:
Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)
-
批准号:9757805
-
项目类别:
-
资助金额:$429.14万
-
财政年份:2015
-
负责人:FRANK SCIURBA
-
依托单位:
Biomarkers predictive of Lung Function Decline in physiologically Normal Smokers
-
批准号:9144848
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2015
-
负责人:FRANK SCIURBA
-
依托单位:
Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)
-
批准号:8955861
-
项目类别:
-
资助金额:$439.73万
-
财政年份:2015
-
负责人:FRANK SCIURBA
-
依托单位:
LTRC CLINICAL CENTER
-
批准号:8429134
-
项目类别:
-
资助金额:$71.28万
-
财政年份:2011
-
负责人:FRANK SCIURBA
-
依托单位:
LTRC CLINICAL CENTER
-
批准号:8602365
-
项目类别:
-
资助金额:$50.62万
-
财政年份:2011
-
负责人:FRANK SCIURBA
-
依托单位:
LTRC CLINICAL CENTER
-
批准号:8355891
-
项目类别:
-
资助金额:$71.37万
-
财政年份:2011
-
负责人:FRANK SCIURBA
-
依托单位:
Clinical
-
批准号:7394643
-
项目类别:
-
资助金额:$37.67万
-
财政年份:2007
-
负责人:FRANK SCIURBA
-
依托单位:
Molecular and Cellular Determinants of Disease Heterogeneity in COPD
-
批准号:7564770
-
项目类别:
-
资助金额:$253.81万
-
财政年份:2007
-
负责人:FRANK SCIURBA
-
依托单位:
Molecular and Cellular Determinants of Disease Heterogeneity in COPD
-
批准号:7750506
-
项目类别:
-
资助金额:$256.99万
-
财政年份:2007
-
负责人:FRANK SCIURBA
-
依托单位:
Molecular and Cellular Determinants of Disease Heterogeneity in COPD
-
批准号:7340183
-
项目类别:
-
资助金额:$251.59万
-
财政年份:2007
-
负责人:FRANK SCIURBA
-
依托单位:
Molecular and Cellular Determinants of Disease Heterogeneity in COPD
-
批准号:7115430
-
项目类别:
-
资助金额:$261.58万
-
财政年份:2007
-
负责人:FRANK SCIURBA
-
依托单位:
Administrative
-
批准号:7394637
-
项目类别:
-
资助金额:$17.06万
-
财政年份:2007
-
负责人:FRANK SCIURBA
-
依托单位:
Molecular and Cellular Determinants of Disease Heterogeneity in COPD
-
批准号:8034694
-
项目类别:
-
资助金额:$257.83万
-
财政年份:2007
-
负责人:FRANK SCIURBA
-
依托单位:
Long-Term Oxygen Treatment Trial (LOTT) - Regional Clinical Center
-
批准号:8751512
-
项目类别:
-
资助金额:$39.65万
-
财政年份:2006
-
负责人:FRANK SCIURBA
-
依托单位:
Long-term Oxygen Treatment Trial
-
批准号:8564497
-
项目类别:
-
资助金额:$21.16万
-
财政年份:2006
-
负责人:FRANK SCIURBA
-
依托单位:
Long-term Oxygen Treatment Trial
-
批准号:8083010
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2006
-
负责人:FRANK SCIURBA
-
依托单位:
LUNG TISSUE RESEARCH CONSORTIUM (LTRC): CLINICAL CENTER
-
批准号:7201145
-
项目类别:
-
资助金额:$0.13万
-
财政年份:2005
-
负责人:FRANK SCIURBA
-
依托单位:
COPD Clinical Research Network
-
批准号:7118251
-
项目类别:
-
资助金额:$52.42万
-
财政年份:2004
-
负责人:FRANK SCIURBA
-
依托单位:
海外基金